21 U.S.C. § 360n-1 — Priority review for qualified infectious disease products

(a) In general If the Secretary designates a drug under section 355f(d) of this title as a qualified infectious disease product, then the Secretary shall give priority review to the first application submitted for approval for such drug under section 355(b) of this title , or section 262(a) of title 42 , that requires clinical data (other than bioavailability studies) to demonstrate safety or effectiveness. (b) Construction Nothing in this section shall prohibit the Secretary from giving priority review to a human drug application or efficacy supplement submitted for approval under section 355(b) of this title that otherwise meets the criteria for the Secretary to grant priority review. (June 25, 1938, ch. 675, § 524A, as added Pub. L. 112–144, title VIII, § 802(a) , July 9, 2012 , 126 Stat. 1079 ; amended Pub. L. 114–255, div. A, title III, § 3101(a)(2)(N) , Dec. 13, 2016 , 130 Stat. 1154 ; Pub. L. 117–328, div. FF, title III, § 3212(b) , Dec. 29, 2022 , 136 Stat. 5826 .) Editorial Notes Amendments 2022—Subsec. (a). Pub. L. 117–328 inserted “, or section 262(a) of title 42 , that requires clinical data (other than bioavailability studies) to demonstrate safety or effectiveness” before period at end. 2016— Pub. L. 114–255 designated existing provisions as subsec. (a), inserted heading, substituted “the first application” for “any application”, and added subsec. (b). Statutory Notes and Related Subsidiaries Effective Date Pub. L. 112–144, title VIII, § 802(b) , July 9, 2012 , 126 Stat. 1079 , provided that: “Section 524A of the Federal Food, Drug, and Cosmetic Act [ 21 U.S.C. 360n–1 ], as added by subsection (a), applies only with respect to an application that is submitted under section 505(b) of such Act ( 21 U.S.C. 355(b) ) on or after the date of the enactment of this Act [ July 9, 2012 ].”

Related documents

• 21 U.S.C. § 355f — Extension of exclusivity period for new qualified infectious disease products#577369
• 42 U.S.C. § 300j-3b — Contaminant standards or treatment technique guidelines#594782
• A Study for Assessing the Efficacy and Safety ParActin® in Individuals With Upper Respiratory Tract Infections#979360
• Supply and delivery of Sequencing reagents and commodities for priority pathogens- v i r a l, bacterial with focus on AMR — Health Emergency Preparedness, Response and Resilience Program Using the Multiphase Programmatic App (Eastern and So#1181427
• Supply and delivery of Sequencing reagents and commodities for priority pathogens- v i r a l , bacterial with focus on AMR — Health Emergency Preparedness, Response and Resilience Program Using the Multiphase Programmatic App (Eastern and S#1181426